Letter

Regulating the pharmaceutical industry

BMJ 1998; 316 doi: 10.1136/bmj.316.7126.226 (Published 17 January 1998)
Cite this as: BMJ 1998;316:226

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

General public does not support value system inherent in cost effectiveness analyses

  1. Jim Furniss, Managing consultanta,
  2. Joe Zammit-Lucia, Directora,
  3. Neil Johnson
  1. aHealth Economics Research Group, Cambridge Pharma Consultancy, European Office, Cambridge CB5 8AB
  2. bAssociation of the British Pharmaceutical Industry, London SW1A 2DY
  3. cOffice of Health Economics, London SW1A 2DY
  4. dNational Economic Research Associates, London W1N 9AF
  5. eAustralian Pharmaceutical Manufacturers’ Association, 77 Berry Street, North Sydney, NSW 2060, Australia
  6. fGlaxoWellcome, London W1X 6BQ
  7. gYork Health Economics Consortium, University of York, York YO1 5DD
  8. hDepartment of Health Sciences and Clinical Evaluation, University of York

    Editor-Some of the recommendations in Maynard and Bloor's editorial on regulating the pharmaceutical industry are reminiscent of the days when the government was generally believed to be the best arbiter of how industry should invest its resources.1

    The authors’ faith in the use of cost effectiveness analysis as a rationing mechanism is perhaps not surprising in view of their professional background. But to our knowledge there is no evidence-for example, from the Australian authorities-that the use of such analysis as a rationing mechanism improves public health. Indeed, some people have argued that it does exactly the opposite. It limits access to new interventions and protects established therapeutic regimens, which are never subjected to the same level of rigorous analysis.

    Moreover, what research there has been suggests that the general public does not support the utilitarian value system inherent in cost effectiveness analyses.2 A rationing system that allocates resources on the basis of probable outcome rather than need does not seem to sit comfortably with current social values. Furthermore, cost effectiveness varies on a patient by patient basis. A system that blocks access to new treatments for the whole population is not reasonable when there are some patients for whom such an intervention is indeed very cost effective.

    In a system constrained by costs, economic efficiency should naturally inform decisions on allocation of resources, but not as a blunt instrument of regulation for limiting access across the whole population. Rather, this is part of the general market in information that will allow healthcare professionals to make sensible decisions on how they treat individual patients.

    The authors’ final suggestion is that there should be government direction of industry's expenditure on research. Financial penalties would siphon funds which could be directed at universities and the Medical Research Council. Again, where is …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular